RxDoctor Payments Data

Lucas Casul, MD

Internal Medicine · Albuquerque, NMNPI 1881751410

Payments from drug & device makers

$657in general payments, 2019–2025

Across 42 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$150
  • Novartis$120
  • Boehringer Ingelheim$63
  • Novo Nordisk$56
  • Astellas Pharma US Inc$45
  • Teva Pharmaceuticals USA, Inc.$41
  • plus $181 from 8 others

What the payments were for

  • Food & beverage$65199%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$657 in reported general payments places this provider in the 80th percentile of 578 internal medicine providers in New Mexico.

See all internal medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$34,851
Medicare patients
183
Services billed
426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide79$87,933
FarxigaDapagliflozin Propanediol104$75,607
XareltoRivaroxaban95$75,460
EliquisApixaban42$39,378
Atorvastatin Calcium646$10,568
Levothyroxine Sodium709$10,367
Gabapentin475$7,522
TradjentaLinagliptin13$7,224
SymbicortBudesonide/Formoterol Fumarate27$6,722
Amlodipine Besylate473$5,786
Fluticasone Propionate HfaFluticasone Propionate29$5,575
Albuterol Sulfate HfaAlbuterol Sulfate158$5,472
Losartan Potassium299$5,342
Tamsulosin Hcl240$5,073
Lisinopril396$4,854

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$56$87,93379 claims
AstraZenecaFarxiga, Symbicort$150$82,329131 claims
PfizerEliquis$38$39,37842 claims
Boehringer IngelheimTradjenta$63$7,22413 claims
AbbVieSynthroid$17$1,92533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 578 internal medicine providers in New Mexico.

Other internal medicine in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →